UK markets closed

Coloplast A/S (COLO-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
906.00+9.80 (+1.09%)
At close: 04:59PM CEST
Full screen
Previous close896.20
Bid904.80 x 0
Ask905.20 x 0
Day's range895.20 - 906.00
52-week range689.20 - 993.00
Avg. volume232,974
Market cap203.691B
Beta (5Y monthly)0.30
PE ratio (TTM)40.65
EPS (TTM)22.29
Earnings date07 May 2024
Forward dividend & yield21.00 (2.32%)
Ex-dividend date08 Dec 2023
1y target est940.00
  • Globe Newswire

    Coloplast A/S - Allocation of Share Options

    Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address: https://investor

  • Globe Newswire

    Coloplast launches Peristeen® Light for people with bowel disorders

    Peristeen Light Peristeen Light is designed to bring relief. It is a hand-held, low-volume transanal irrigation device that instills water into the rectum, thereby evacuating the stool from the lower bowel. The new transanal irrigation device is designed to help people facing defecation issues or stool leakage. It is estimated that 10-15% of the world’s population are affected by chronic constipation1 and that 6% struggle with faecal incontinence2, both of which can cause physical discomfort and

  • Globe Newswire

    Coloplast A/S - Interim Financial Report, Q1 2023/24

    Q1 2023/24Interim financial results, Q1 2023/241 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin1) of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies. Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 9% (Advanced Wound Dressings 9%) and Interventional Urology